Multiple Myeloma Genomics Initiative (MMGI)
The most exciting and promising area in multiple myeloma research is personalized medicine. In 2005 we launched the multimillion-dollar Multiple Myeloma Genomics Initiative (MMGI) to accelerate the development of therapies tailored to DNA alterations in myeloma cells.
Landmark study P=published
Less than six years later, researchers published a landmark study in Nature analyzing 38 multiple myeloma genome sequences—the largest such data set ever published in multiple myeloma.
A comprehensive genome database
Today the MMGI stands as the most extensive research collaboration ever focused on the genomics of multiple myeloma. Our funding of the project, and our development of a model for collaboration among two world-class genomics centers — the Broad Institute and the Translational Genomics Research Institute (Tgen) — as well as leading multiple myeloma experts, has resulted in:
- an invaluable centralized repository of high-quality myeloma genomic information
- engagement with a research community of nearly 600 registered members
- open access, high resolution data available to researchers in real-time through the Initiative’s Genomics Portal
- cutting-edge bioinformatics tools to help analyze and interpret data
Uncovering novel connections
By analyzing samples from our tissue bank, the MMGI has uncovered novel connections between the disease and important molecular targets. We are conducting studies targeting key proteins that might be driving the disease, and engaging with industry partners who have promising molecules that may effectively inhibit these proteins. It has improved the understanding of how multiple myeloma develops, and accelerated our ability to identify specific subtypes and design therapies to treat them.